Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

CSE:RVV - Post by User

Revive Therapeutics Ltd. > Funding

<< Previous

Bullboard Posts

Next >>

Comment by 90guppyon Aug 04, 2020 8:53pm

123 Views

Post# 31364544

RE:RE:Funding

RVV has enough money to finish the trials. In the Management Discussion Analysis submitted on May 29th, on page 14, you will see the amount that they will need to finish the trials. According to the MD&A, they will need only $200k to finish it.
https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00034460&issuerType=03&projectNo=03066479&docId=4736154

mrnormal wrote:
Yuppers, that's been an ace up our sleeve for sure.

I think Michael went on radio silence after that was shared. For good reason. He's a pretty tight lipped guy.